We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ambrx Biopharma Inc | NASDAQ:AMAM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.00 | 27.92 | 25.00 | 0 | 01:00:00 |
From Nov 2023 to May 2024
1422 ET -- Johnson & Johnson and Merck & Co. are two of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. J&J will acquire Ambrx Biopharma in a deal with a total equity value of about $2 billion. Merck agreed to buy Harpoon Therapeutics for about $680 million. In both transactions, the per-share deal value is more than twice the Friday closing price. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
January 08, 2024 14:39 ET (19:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Ambrx Biopharma Chart |
1 Month Ambrx Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
